Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could Increase Patient Participation and Drive More Comprehensive Therapeutic Evaluation CAMBRIDGE, Mass. , July 24, 2024 ...
Revolutionary Test to Address Cellular Fragility Syndrome and Promote Longevity SAN DIEGO , July 23, 2024 /PRNewswire-PRWeb/ -- Seraphina Therapeutics, the pioneer in healthspan-extending nutrient research, is proud to announce a ...
COLORADO SPRINGS, Colo. , July 22, 2024 /PRNewswire/ -- There is a potential connection between a diagnosis of certain gastrointestinal (GI) syndromes and the formation and rupture of intracranial (brain) aneurysms, according to research ...
SHANGHAI , July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, ...
Research Project with Tel Aviv University to Focus on Optimizing Identification of Early-Stage Dementia and Improving Diagnosis and Treatment for Neurological Conditions HERZLIYA, Israel , July 2, 2024 /PRNewswire/ -- Corundum ...
SHANGHAI , NANJING , CHINA , and SAN JOSE, Calif. , July 1, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ...
NANJING , China , June 17, 2024 /PRNewswire/ -- At the recent European League Against Rheumatism (EULAR) Congress in Vienna, Austria , Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) delivered an oral presentation on its highly ...
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data AUSTIN, Texas , June 14, 2024 /PRNewswire/ -- Mindbloom , the leading ...
ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed Results from the ADESOS study have been selected for an oral presentation at the late ...
Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p<0.0096) Multiple ...
Women get less restorative sleep than men because of their lifestyles and caregiving roles. They sleep less and wake up more often. A new study published in the journal Scientific Reports experimented on mice to find the sleep ...
Neonatal hypoxic-ischemic encephalopathy (HIE) is a brain dysfunction condition in newborns due to inadequate oxygen and blow flow to the brain at term or near birth. It affects 1-2 per 1,000 live births in high-resource countries . HIE is the reason for the deaths of over half a million worldwide each year. Therapeutic hypothermia is the standard treatment for moderate to severe HIE. Many infants treated with hypothermia still experience significant motor, cognitive and behavioral disabilities by school age. In low-income regions therapeutic hypothermia is unavailable and the need for new, accessible treatment is urgent. Therapies for Neuroprotection in Neonatal Hypoxic-Ischemic Encephalopathy A recent review has highlighted cutting-edge approaches to protect the newborn brain. These therapies target complex mechanisms of HIE related brain injury including inflammation, oxidative stress and cell death. Anti-excitotoxic agents like magnesium sulfate and xenon can limit brain damage caused by excessive glutamate release. Antioxidants such as allopurinol and melatonin reduce oxidative stress and improve the condition when combined with other therapies. Multi-mechanism agents like cannabidiol and caffeine promote neuroregeneration while addressing multiple pathways of injury. Stem cell therapy can repair brain damage through regenerative mechanisms. Challenges in Implementing Alternative Therapies Preclinical studies show promising results but implementing these therapies into effective clinical treatments for neonatal HIE presents many difficulties: Identifying the ideal time for administering neuroprotective therapies with the timing of hypoxic-ischemic events is important. The timing, severity and location of brain injury in hypoxic-ischemic encephalopathy can vary significantly between individuals. Need for reliable biomarkers that can assess the severity and progression of brain injury in real time, which can lead to more personalized and accurate treatment. Safe and effective delivery of these therapies to infants poses a significant challenge. Advancements in personalized medicine and combined therapies can improve treating newborns with HIE. The development of affordable and accessible treatments can revolutionize care for this life-altering condition and give hope to families. Reference: Neuroprotection for neonatal hypoxic-ischemic encephalopathy: a review of novel therapies evaluated in clinical studies- (https:...
A new study has revealed that young adults at risk of psychosis exhibit reduced brain connectivity, a deficiency that seems to be exacerbated by cannabis use. This finding opens the door for developing treatments for psychosis that address symptoms ...
Vagus nerve stimulation may help alleviate the symptoms of inflammatory bowel disease (IBD), suggests a new study. According to a team of researchers at Duke University School of Medicine, targeting the nervous system could help reduce the ...
Cardiovascular disease and dementia are major public health concerns that place a substantial strain on healthcare systems and society. A recent study from the Karolinska Institute in Sweden reveals that prolonged use of commonly prescribed ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers